IN-DATE
VPR-GW-14: CSI ViperWire Advance Guidewire 0.014" x 335cm
Sign in to add this product to your favorites!
| Price: | $30.00 EACH |
|---|---|
| Quantity: | |
| In Stock: | 52 eaches |
| Status: | expired |
Related Items
QUICK VIEW
| VPR-GW-14 - Size: 0.014" $149.00 per box of 5 CSI ViperWire Advance Guidewire 0.014" x 335cm Expired Units in stock: 2 box of 5 | Order Qty |
QUICK VIEW
| VPR-GW-17 - Size: 0.017" $9.00 EACH CSI ViperWire Advance Guidewire 0.017" x 335cm Expired Units in stock: 64 | Order Qty |
|
QUICK VIEW
| VPR-GW-17 - Size: 0.017" $45.00 per box of 5 CSI ViperWire Advance Guidewire 0.017" x 335cm Expired Units in stock: 12 box of 5 | Order Qty |
|
QUICK VIEW
| VPR-GW-FLEX14 - Size: 0.014" $15.00 EACH CSI ViperWire Advance Guidewire 0.014" x 335cm, Flex Tip Expired Units in stock: 53 | Order Qty |
|
QUICK VIEW
| VPR-GW-FLEX14 - Size: 0.014" $113.75 per box of 5 CSI ViperWire Advance Guidewire 0.014" x 335cm, Flex Tip Expired Units in stock: 10 box of 5 | Order Qty |
Additional Details
Abbott CSI ViperWire Advance™ & ViperWire Advance™ with Flex Tip Peripheral Guide Wires
ViperWire Advance™ and ViperWire Advance™ with Flex Tip Peripheral Guide Wires are designed specifically for the Diamondback 360™ Peripheral Orbital Atherectomy Systems to facilitate proper device placement within the peripheral artery to enable orbital gain during PAD treatment.
Manufacturer
Cardiovascular Systems, Inc. (CSI), now a part of Abbott, specialized in innovative solutions for the treatment of peripheral and coronary artery disease through its proprietary orbital atherectomy systems. CSI’s flagship technologies include the Diamondback 360® Peripheral Orbital Atherectomy System and the Diamondback 360® Coronary Orbital Atherectomy System, both designed to modify calcified plaque and improve vessel compliance prior to stent placement or balloon angioplasty.
These systems use a diamond-coated crown that orbits within the vessel, sanding away plaque while preserving healthy tissue and facilitating better device delivery. CSI’s focus on challenging arterial disease—particularly in heavily calcified lesions—made it a valuable addition to Abbott’s vascular portfolio following its acquisition in 2023, further expanding minimally invasive treatment options for complex cardiovascular cases.
